

iBio, Inc.
Form 10-K/A
October 15, 2012

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

FORM 10-K/A

(Amendment No. 1)

Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the fiscal year ended June 30, 2012

OR

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _____ to _____

Commission File Number 001-35023

iBio, Inc.
(Exact name of small business registrant in its charter)

Delaware 26-2797813

(State or other jurisdiction of (I.R.S. Employer Identification
incorporation or organization) No.)

9 Innovation Way, Suite
100, Newark, DE 19711

(Address of principal executive
offices) (Zip Code)

(302) 355-0650

(Registrant's telephone number, including Area Code)

Securities registered under Section 12(b) of the Exchange Act:

Title of Each Class	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NYSE MKT

Securities registered under Section 12(g) of the Exchange Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes No

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to

such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to

the best of
Registrant's
knowledge, in
definitive
proxy or
information
statements
incorporated
by reference
in Part III of
this Form
10-K or any
amendment to
this Form
10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer", "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated Filer
Accelerated Filer
Non-accelerated Filer
Smaller reporting company

Indicate by
check mark
whether the
registrant is a
shell
company (as
defined in
Rule 12b-2 of
the Exchange
Act).

Yes No

The
aggregate
market value
of the voting
stock held by
non-affiliates
of the
Registrant
based on the
trading price
of the
Registrant's

Common
Stock on June
30, 2012 was
\$22,339,800

The number
of shares
outstanding
of each of the
Registrant's
classes of
common
equity, as of
the latest
practicable
date:

Class	Outstanding at September 14, 2012
Common Stock, \$0.001 par value	47,767,095 Shares

Explanatory Note

The purpose of this Amendment No. 1 to the Annual Report on Form 10-K of iBio, Inc. for the year ended June 30, 2012, filed with the Securities and Exchange Commission on October 12, 2012 (the "Form 10-K"), is solely to furnish Exhibit 101 to the Form 10-K in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the financial statements and related notes from the Form 10-K formatted in XBRL (eXtensible Business Reporting Language).

No other changes have been made to the Form 10-K. This Amendment No. 1 to the Form 10-K speaks only as of the original filing date of the Form 10-K, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-K.

Item 15. Exhibits and Financial Statement Schedules

Number	Description
3.1	Certificate of Incorporation of the Company (1)
3.2	Certificate of Amendment of the Certificate of Incorporation of the Company (2)
3.3	Bylaws of the Company (3)
4.1	Form of Common Stock Certificate (1)
4.2	Form of Investor Warrant (2008) (4)
4.3	Form of Investor Warrant (2010) (5)
10.1	Technology Transfer Agreement, dated as of January 1, 2004, between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. (6)
10.2	Non-Standard Navy Cooperative Research and Development Agreement, dated August 17, 2004, between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. (6)
10.3	Supply License Agreement, dated as of March 22, 2006, between the Company and Mannatech, Inc.

- 10.4 (6)
Form of
Registration Rights
Agreement (2008)
- 10.5 (4)
Form of
Registration Rights
Agreement (2010)
- 23.1 (5)
Consent of
Independent
Registered Public
Accounting Firm
- 31.1 (7)
Certification of
Periodic Report by
Chief Executive
Officer Pursuant to
Rule 13a-14 and
15d-14 of the
Securities
Exchange Act of
1934, as adopted
pursuant to Section
302 of the
Sarbanes-Oxley
Act of 2002 (7)
- 31.2 Certification of
Periodic Report by
Chief Financial
Officer Pursuant to
Rule 13a-14 and
15d-14 of the
Securities
Exchange Act of
1934, as adopted
pursuant to Section
302 of the
Sarbanes-Oxley
Act of 2002 (7)
- 32.1 Certification of
Periodic Report by
Chief Executive
Officer Pursuant to
18 U.S.C. Section
1350, as adopted
pursuant to Section
906 of the
Sarbanes-Oxley
Act of 2002 (7)
- 32.2

Certification of
Periodic Report by
Chief Financial
Officer Pursuant to
18 U.S.C. Section
1350, as adopted
pursuant to Section
906 of the
Sarbanes-Oxley
Act of 2002 (7)
XBRL

101.INS INSTANCE
DOCUMENT (8)

XBRL

101.SCH TAXONOMY
EXTENSION
SCHEMA (8)

XBRL

TAXONOMY

101.CAL EXTENSION
CALCULATION
LINKBASE (8)

XBRL

TAXONOMY

101.DEF EXTENSION
DEFINITION
LINKBASE (8)

XBRL

TAXONOMY

101.LAB EXTENSION
LABEL
LINKBASE (8)

XBRL

TAXONOMY

101.PRE EXTENSION
PRESENTATION
LINKBASE (8)

(1) Incorporated herein by reference to the Company's Form 10-12G filed with the SEC on July 11, 2008.

(2) Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on December 15, 2010.

(3) Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on August 14, 2009.

(4) Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on August 21, 2008.

(5)

Edgar Filing: iBio, Inc. - Form 10-K/A

Incorporated herein by reference to the Company's Quarterly Report on Form 10-Q filed with the SEC on November 15, 2010.

- (6) Incorporated herein by reference to the Company's Form 10-12G filed with the SEC on June 18, 2008.
 - (7) Previously filed.
 - (8) In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 in this report on Form 10-K shall be deemed "furnished" and not "filed."
-

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on October 12, 2012.

iBio, Inc.

By: /s/ Robert B. Kay
 Robert B. Kay
 Chief Executive Officer

In accordance with the Securities Exchange Act, this report has been signed below by the following persons on behalf of iBio, Inc. and in the capacities and on the dates indicated:

Signature	Title	Date
/s/ Robert B. Kay Robert B. Kay	Chief Executive Officer and Director (Principal Executive Officer)	October 12, 2012
/s/ Glenn Chang Glenn Chang	Director	October 12, 2012
/s/ Arthur Y. Elliott Arthur Y. Elliott, Ph.D.	Director	October 12, 2012
/s/ James T. Hill General James T. Hill (Ret.)	Director	October 12, 2012
/s/ Douglas Beck Douglas Beck, CPA	Chief Financial Officer (Principal Financial and Accounting Officer)	October 12, 2012
/s/ John D. McKey, Jr. John D. McKey, Jr.	Director	October 12, 2012
/s/ Philip K. Russell Philip K. Russell, M.D.	Director	October 12, 2012
/s/ Jules Müsing Jules Müsing	Director	October 12, 2012
